Cigna Corporation Earnings Recaps
Q1 2026
May 1, 2026
Shares of Cigna Group declined 3.2% post-earnings, as investor disappointment centered on the company's cautious full-year 2026 outlook despite management highlighting raised adjusted EPS guidance. The market response suggests concerns about decelerating growth, possibly tied to margin pressures or uncertainty in addressing rising healthcare costs.
Key takeaways
- Cigna reported Q1 revenue of $68.5 billion and adjusted EPS of $7.79.
- The company slightly raised its full-year 2026 adjusted EPS outlook to at least $30.35.
- Management emphasized efforts to address affordability and streamline healthcare access, including a 15% reduction in prior authorizations.
- A new rebate-free pharmacy service model (“Signature”) was introduced, targeting price transparency and reduced brand drug costs.
- The CEO transition to Brian Evanko is on track for July 1, with continued focus on cost control and innovation amid ongoing industry pressures.
Q3 2025
Nov 1, 2025
Cigna Group demonstrated resilient performance in the third quarter of 2025, delivering strong revenue growth of $69.7 billion and adjusted earnings per share of $7.83 while strategically investing in innovation and expanding market access.
Key takeaways
- Revenue reached $69.7 billion, reflecting robust growth amid ongoing market disruptions.
- Adjusted earnings per share improved to $7.83, bolstered by strategic investments and operational efficiencies.
- Introduced a groundbreaking rebate-free model for pharmacy benefits, aimed at enhancing affordability and consumer experience.
- Completed a strategic investment in Shields Health Solutions to expand addressable markets and position for future growth.
- Demonstrated commitment to improving drug affordability, particularly for generic medications, now accounting for 90% of prescriptions in the U.S.